Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results